Obesity Clinical Trials in Indianapolis, Indiana

12 studies are recruiting for obesity in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Ascension Medical Group, Indianapolis, Indiana

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Indianapolis, Indiana

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Indianapolis, Indiana

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

4. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   DM Clinical Research - Indianapolis, Indianapolis, Indiana

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

5. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

   The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may inclu…

   Stage

   Phase 3

   Ages

   12 to 17

   Site

   Indiana University Health University Hospital, Indianapolis, Indiana

   Locations

   69 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06439277 on ClinicalTrials.gov

6. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

   The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Whic…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Midwest Inst For Clin Res, Indianapolis, Indiana

   Locations

   36 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07745504 on ClinicalTrials.gov

7. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide …

   Stage

   Phase 3

   Ages

   8 to 18

   Site

   IU Health - Riley Physicians Endo-Diab, Indianapolis, Indiana

   Locations

   121 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07253285 on ClinicalTrials.gov

8. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Riley Hospital for Children, Indianapolis, Indiana

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

9. The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

   Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweigh…

   Stage

   Phase 2

   Ages

   11 to 18

   Site

   Indiana University School of Medicine, Indianapolis, Indiana

   Run by

   Heba M. Ismail

   See if you can join NCT05414409 on ClinicalTrials.gov

10. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Indiana University Health Methodist Hospital, Indianapolis, Indiana

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

11. Fibrosis Lessens After Metabolic Surgery

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease aff…

    Stage

    Phase 4

    Ages

    18 to 75

    Site

    Indiana University, Indianapolis, Indiana

    Locations

    22 in total

    Run by

    The Cleveland Clinic

    See if you can join NCT06374875 on ClinicalTrials.gov

12. AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Midwest Inst For Clin Res, Indianapolis, Indiana

    Locations

    72 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07339423 on ClinicalTrials.gov